window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

About Sebastien

This author has not yet filled in any details.
So far Sebastien has created 4 blog entries.

Novigenix to Present Data on New Molecular Signature for Early Detection of Colon Cancer at ESMO 2019

By |2019-09-11T14:34:45+02:0010 September 2019|Communiqué de presse, News Novigenix|

Company Launches New Website to Enhance New Strategy Company to present at the Convergence of Oncology meeting in Lausanne LAUSANNE, SWITZERLAND - 07:00 CET, September 10, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the discovery of a new molecular signature

Novigenix acquires blood-based molecular diagnostics test Colox® and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer

By |2018-04-04T15:19:05+02:0012 February 2015|Communiqué de presse|

LAUSANNE, Switzerland, February 12, 2015 – Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox